Fluoroquinolone antimicrobial agents are highly active against aerobic or facultative gram-negative bacilli. The fluoroquinolones have been shown to be very concentration dependent in their rates of killing and also have a postantibiotic effect against most gram-negative pathogens. These properties resemble those of aminoglycosides more than those of the b-lactam antibiotics. In animal studies, once daily administration of a dose that produced a high peak concentration/minimal inhibitory concentration (MIC) ratio of ú10 -20:1 resulted in significantly better survival than did regimens in which the same daily dose was used on a more fractionated schedule. Studies in patients, most often with ciprofloxacin, demonstrated that the area under the concentration-time curve (AUC)/ MIC ratio (AUIC) is the most important predictor of both clinical and microbiological cure. These findings, when combined with microbiological and pharmacokinetic data, provide the rationale and tools needed for targeting the dosage of fluoroquinolones to individual patients on the basis of pharmacokinetics and the susceptibilities of the bacterial pathogens.
The pharmacology of antimicrobial therapy can be separated aerobic or facultative gram-negative bacilli. They have been shown to be mostly concentration dependent in their rates of into two distinct components. The first of these is pharmacokinetics, which deals with absorption, distribution, and elimina-killing. This characteristic makes them resemble aminoglycosides more than b-lactam antibiotics in terms of their microbio-tion of antimicrobials. It is these factors that determine the time course of antimicrobial concentrations in serum and tis-logical properties. In this review we will analyze the most important findings based on in vitro and animal data, as well sues during a given dosing regimen. Pharmacodynamics, the second component, concerns the relationship between concen-as results derived from treatment of human infections, to evaluate the most important pharmacodynamic factors regarding this tration and the antimicrobial effect. The time course of antimicrobial therapy is a reflection of the interrelationship between class of antibiotics. pharmacokinetics and pharmacodynamics [1] .
Recent in vitro studies and animal-dose-response studies Microbiology have determined two important antibacterial pharmacodynamic
The fluoroquinolones currently in clinical use are all structurparameters that differ among antimicrobial agents with diverse ally similar and have N-1-substituted 1, 4-dihydro-4-oxo-pyrimechanisms of action and better describe the time course of dine-3-carboxylic acid moiety as the basic nucleus. During the antibacterial activity than do simple MIC determinations. Antipast decade, chemists have been able to make a number of microbial agents that inhibit protein or nucleic acid synthesis modifications to the quinolone molecule, primarily at the N-1 all induce a postantibiotic effect (PAE) against most bacterial position and the C-6, C-7, and C-8 positions. The modifications strains tested, whereas penicillins and cephalosporins, which have led to some significant changes in the antimicrobial activinhibit cell-wall synthesis, induce a PAE against Staphylococity, pharmacokinetic profiles, and metabolic properties of the cus aureus but not against gram-negative bacilli [2 -5] . In addinewer fluoroquinolones. The newer fluoroquinolones exhibit a tion, aminoglycosides exhibit concentration-dependent bacteribroad spectrum of antibacterial activity evidenced by procidal activity at levels above the MBC, whereas b-lactams nounced activity against aerobic gram-negative bacteria, partictypically do not [6] .
ularly Enterobacteriaceae, but also against gram-positive patho-Fluoroquinolone antimicrobial agents have been available to gens such as staphylococci, including methicillin-resistant physicians for 10 years. These agents are highly active against strains (table 1) [7] . Like the aminoglycosides, all fluoroquinolones exhibit a PAE and a concentration-dependent antibacterial activity at levels above the MIC [8] . In addition, it has been demonstrated This article is part of a series of papers presented at a symposium entitled ''Pharmacodynamics of Antimicrobials'' that was held on 21 -23 July 1995 that ciprofloxacin and ofloxacin are active against stationary- [7] . ND Å not determined.
The interaction of ciprofloxacin with bacterial membranes With respect to the concentrations needed, the PAE and membrane-disrupting effect differ in that PAE is mediated by is concentration dependent. Ciprofloxacin exhibited a maximal effect on the outer membrane at a concentration of 1 mg/L, sub-MIC concentrations, whereas the membrane disintegration is mediated by concentrations above the MIC. Although studies which was 10 times the MIC for the test organism. The cytoplasmic membrane disintegrates in the presence of 10 mg of of the interaction of quinolones and aminoglycosides with bacterial membranes were not designed to determine whether im-ciprofloxacin/L; thus, the effect of ciprofloxacin on the outer bacterial membrane may be of physiological relevance, proved in vivo efficacy may be associated with this pharmacodynamic parameter, these studies offer additional evidence as whereas the effect on the cytoplasmic membrane is achieved only at nonphysiological concentrations. The membrane-dis-to the importance of high peak concentrations. Fluoroquinolones are bactericidal, and this effect is concentration depen-rupting activity may contribute to the efficacy of these fluoroquinolones against stationary-phase bacteria. dent. This effect was elegantly shown in experiments conducted in the mid-1980s [14] . However, killing of bacteria by fluoro-These specific attributes of ciprofloxacin, pefloxacin, and fleroxacin may contribute to their in vivo efficacy in immuno-quinolones exhibits a paradoxical effect. Above a certain concentration for each fluoroquinolone, less bactericidal activity competent and immunocompromised mice; ED 50 (median effective dose) values for these two agents differ only minimally is evident. This paradoxical effect is possibly explained by the observation that at high drug concentrations, synthesis of RNA under these experimental conditions, where the other fluoroquinolones are remarkably less effective in immunosuppressed and protein, both of which are necessary for killing, is inhibited [14, 15] . animals than in immunocompetent animals (table 2) [8, 13] . Table 2 . Correlation between in vitro activity, in vivo efficacy against Escherichia coli ''Juhl,'' and pharmacokinetic parameters of ten fluoroquinolones in mice after a single sc dose. serum bactericidal concentrations observed in humans [20] . NOTE. Data are from [16] . AUC Å area under the concentration-time curve; Studies with ciprofloxacin against Pseudomonas aeruginosa C max Å maximum plasma concentration; ND Å not determined; T 1/2b Å elimination have shown that even sub-MIC concentrations of drug can half-life; T max Å time to peak serum concentration; V d Å volume of distribution.
* Single oral 400-mg dose in healthy subjects.
result in a reduction of £99% in the number of bacteria during 4 hours after a simulated 200-mg iv dose; however, regrowth of bacterial subpopulations resistent to §4 mg/L are detected after 4 -6 hours [20] . Such a staggered dose of a similar size Pharmacokinetics had no effect on bacterial growth. These observations are explained by the presence of bacterial subpopulations with vary-The pharmacokinetic properties of the newer fluoroquinoing susceptibilities to ciprofloxacin: some of these subpopulalones have been well documented [16] , as have the tissue distritions are highly susceptible, while others are resistant to bution characteristics of these drugs [17] . Representative pharconcentrations of drug simulated in the in vitro model [21] . macokinetic parameters, shown in table 3 [16] , indicate the Blaser and colleagues [22] have shown in experiments with following properties: peak serum concentrations vary from 1.5 P. aeruginosa that high values of the peak enoxacin concentramg/L for norfloxacin and ciprofloxacin to twofold-to-threefold tion above the MIC were associated with a greater reduction higher values for ofloxacin and fleroxacin; time to peak serum in initial bacterial inoculum at 4 hours and 24 hours; values concentrations are similar for all quinolones, at about 2 hours; of õ8:1 were associated with net bacterial regrowth by 24 and elimination half-lives (T 1/2b ) are long, varying from 3. profloxacin with the MICs for the persistent strains and with were observed, which declined 12 hours later to 0.070 { 0.025 ciprofloxacin dosing. The bactericidal kinetics against a Klebmg/L [19] . A good dose-concentration response and linear siella pneumoniae strain for which the MIC was 0.5 mg/L pharmacokinetics were evident (table 4).
indicated that during exposure to ciprofloxacin simulating a 3 As suggested by the high apparent volume of distribution 1 400-mg dosing, ú99.99% (4 log) of the initial number of cfu (V d ), together with low protein binding, fluoroquinolone con-(10 6 /mL) were killed. Survivors were reduced to a minimum centrations in body tissues and fluids are higher or similar to number of 3.5 1 10 1 /mL. This lowest count was reached after blood concentrations. With the fluoroquinolones, tissue con-18 hours. After 26 hours the number of cfu was 8.5 1 centrations are generally high as a result of a high bioavailabil-10 1 /mL ( figure 2) . The MIC for this Klebsiella strain (0.5 ity of 70% -ú95% when these drugs are administered orally; mg/L) remained unchanged throughout the 26 hours of expolow protein binding, ranging from 10% to 30%; and isoelectric sure to ciprofloxacin. In this model the three-times-daily dosing points in plasma ranging from 6.8 to 7.5, indicating that fluoof ciprofloxacin was superior to a two-times-daily dosing, at roquinolones are in the least ionized state while circulating in least for pathogens of borderline susceptibility. serum. Consequently, the major fraction of the quinolones can diffuse freely from the intravascular to the extravascular space [17] . Liposolubility, which is usually advocated as a drug factor that produced a high peak concentration/MIC ratio (Ç20:1) (õ10:1) peak concentration/MIC ratios, did not show this effect, as once-daily and twice-daily regimens produced equiva-produced significantly better survival than did regimens in which the same daily dose was used, but on a more fractionated lent results. Challenge with resistant mutants selected for altered MICs of fluoroquinolones (two and four times the MIC schedule ( figure 3) . The use of a smaller dose, producing lower for the parent strain) resulted in markedly diminished survival. Challenge with the parent strain and use of a drug dose that produced a peak concentration/MIC ratio identical to that for animals challenged with the mutant, for which the MIC was four times that for the parent strain, and treated with the larger drug dose produced survival curves that were not different. For this animal model, the peak concentration/MIC ratio was linked to survival, particularly when high ratios (10:1 to 20:1) were obtained. At lower doses producing peak concentration/ MIC ratios of õ10:1, the AUC relative to the MIC appeared to be most closely linked to outcome. The time that levels in plasma exceeded the MIC did not influence survival. The authors modeled the dose-response relationship according to a modified Hill's model and derived an excellent relationship (r 2 Å 0.22) with the peak concentration/MIC ratio as well as the AUC/MIC ratio. However, the authors also stressed that very large doses of some fluoroquinolones, as would be given on a once-or twice-daily schedule, might be toxic.
Human Studies
Only a few studies have been conducted in humans to confirm the hypothesis generated by in vitro models. Peloquin et al. [25] reported on pharmacodynamic determinants for eradication of bacteria from the tracheobronchial secretions of intu- tion of pathogens from the lower respiratory tract.
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06-17-98 17:09:07 cida UC: CID CID 1998;27 (July) Pharmacodynamics of Fluoroquinolones probabilities of clinical and microbiological cures were 42% and 26%, respectively. At an AUIC of ú125 (45 patients), the probabilities were 80% (P õ .001), respectively. There were two significant breakpoints in the time-to-bacterial-eradication data. At an AUIC of õ125 (21 patients), the median time to eradication exceeded 32 days; at an AUIC of 125 -250 (15 patients), time to eradication was 6.6 days; and at an AUIC of ú250 (28 patients), the median time to eradication was 1.9 days (groups differed significantly; P õ .005).
It should be pointed out that the univariate analysis in the study of Forrest et al. [27] identified the AUIC, MIC, and several other drug exposure measures (peak concentration/MIC ratio, trough concentration/MIC ratio, and the percentage of time above the MIC) as being significantly associated with outcome. In the multivariate analysis, with an AUIC in the equation, none of the other factors were statistically significant. All three pharmacodynamic analyses (likelihood of clinical cure and microbiological cure and time to bacterial eradication) independently identified an AUIC of 125 SIT 01 1 h, as a critical breakpoint in defining the adequacy of therapy. At an AUIC of õ125, the probability of treatment failure was highly the intensive care unit.
In extrapolating these results to infections induced by Streptococcus pneumoniae or S. aureus, it must be taken into consid-In several intensive care unit studies of the research group in Buffalo [26, 27] , data were obtained for 74 patients with eration that at clinically achievable concentrations, ciprofloxacin, for example, killed P. aeruginosa more rapidly than either acute infections treated with ciprofloxacin in two clinical efficacy trials. These investigators developed a population pharma-S. pneumoniae or S. aureus [28] . Hyatt et al. assessed the serum bactericidal activity of ciprofloxacin against strains of cokinetic model and an optimal sampling strategy for iv ciprofloxacin treatment and used these data to model the S. pneumoniae, S. aureus, and P. aeruginosa, for which MICs were similar (0.4 mg/mL) in serum ultrafiltrates from five pharmacodynamic relationships between ciprofloxacin exposure and response. Endotracheal samples from patients were healthy volunteers receiving iv ciprofloxacin (400 mg every 8 cultured frequently so that the day of bacterial eradication could be determined. The pharmacokinetic data were fitted by iterative two-stage analysis, assuming a linear two-compartment model. Logistic regression was used to model ciprofloxacin exposure (and other potential covariates) vs. the probabilities of achieving clinical and microbiological cures. The same variables were also modeled vs. the time to bacterial eradication by proportional hazards regression. The independent variables considered were dose; site of infection; infecting organism and the MIC for it; percentage of time above the MIC; peak concentration, peak concentration/MIC ratio, trough concentration, trough concentration/MIC ratio, 24-hour AUC, and AUIC; the presence of other active antibacterial agents; and patient characteristics.
The most important predictor for all three measures of ci- hours) [28] . Time-kill curve studies were performed with low (1.55 -2.48 mg/mL), intermediate (6.0 -7.42 mg/mL), and high (15-25 mg/mL) concentrations of ciprofloxacin against the three organisms. At low concentrations (three to six times the MIC), AUC 24 /MICs were õ125 for two of five volunteers, and and the killing rates were similar for the three organisms. A paradoxical decrease in the killing rate was seen at high concentrations (35 to 60 times the MIC). pharmacodynamic considerations. On the basis of the pharmacodynamic properties of the fluoroquinolones -shown in ani-Conclusion mal models and in patients -it can be concluded that regimens The above data indicate that efficacy in antimicrobial therapy of large doses (resulting in high AUCs and AUICs) given at may be influenced by microbiological, pharmacokinetic, and infrequent intervals (thus relying on the PAE) might be most efficacious in terms of bacterial killing, eradication time, and reducing the selection of resistant bacteria. The three AUIC groups differed significantly (P õ .005).
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